BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shirai Y, Okazaki Y, Inoue Y, Tamura Y, Yasuoka H, Takeuchi T, Kuwana M. Elevated levels of pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis. Arthritis Rheumatol 2015;67:498-507. [PMID: 25385504 DOI: 10.1002/art.38953] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Perosa F, Favoino E, Favia IE, Vettori S, Prete M, Corrado A, Cantatore FP, Valentini G. Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease. Medicine (Baltimore) 2016;95:e3931. [PMID: 27336883 DOI: 10.1097/MD.0000000000003931] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
2 Colmenares Roldán LM, Velásquez Franco CJ, Mesa Navas MA. Capillaroscopy in systemic sclerosis: A narrative literature review. Revista Colombiana de Reumatología (English Edition) 2016;23:250-8. [DOI: 10.1016/j.rcreue.2016.12.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Hashimoto R, Lanier GM, Dhagia V, Joshi SR, Jordan A, Waddell I, Tuder R, Stenmark KR, Wolin MS, McMurtry IF, Gupte SA. Pluripotent hematopoietic stem cells augment α-adrenergic receptor-mediated contraction of pulmonary artery and contribute to the pathogenesis of pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2020;318:L386-401. [PMID: 31913656 DOI: 10.1152/ajplung.00327.2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ramirez GA, Rovere-Querini P, Blasi M, Sartorelli S, Di Chio MC, Baldini M, De Lorenzo R, Bozzolo EP, Leone R, Mantovani A, Manfredi AA, Tombetti E. PTX3 Intercepts Vascular Inflammation in Systemic Immune-Mediated Diseases. Front Immunol 2019;10:1135. [PMID: 31191526 DOI: 10.3389/fimmu.2019.01135] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
5 Del Papa N, Pignataro F. The Role of Endothelial Progenitors in the Repair of Vascular Damage in Systemic Sclerosis. Front Immunol. 2018;9:1383. [PMID: 29967618 DOI: 10.3389/fimmu.2018.01383] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
6 Nonato CP, Azevedo BLPA, Oliveira JGM, Gardel DG, de Souza DCN, Lopes AJ. The Glittre Activities of Daily Living Test in women with scleroderma and its relation to hand function and physical capacity. Clin Biomech (Bristol, Avon) 2020;73:71-7. [PMID: 31951978 DOI: 10.1016/j.clinbiomech.2020.01.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Ota Y, Kuwana M. Endothelial cells and endothelial progenitor cells in the pathogenesis of systemic sclerosis. Eur J Rheumatol 2020;7:S139-46. [PMID: 31922471 DOI: 10.5152/eurjrheum.2019.19158] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
8 Hasanpur K, Nassiri M, Hosseini Salekdeh G. The comparative analysis of phenotypic and whole transcriptome gene expression data of ascites susceptible versus ascites resistant chickens. Mol Biol Rep 2019;46:793-804. [PMID: 30519813 DOI: 10.1007/s11033-018-4534-8] [Reference Citation Analysis]
9 Allanore Y, Distler O, Matucci-cerinic M, Denton CP. Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis. Arthritis Rheumatol 2018;70:162-70. [DOI: 10.1002/art.40377] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
10 Alhendi FJ, Werth VP, Sollecito TP, Stoopler ET. Systemic sclerosis: Update for oral health care providers. Spec Care Dentist 2020;40:418-30. [PMID: 33448431 DOI: 10.1111/scd.12492] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Pulito-Cueto V, Remuzgo-Martínez S, Genre F, Atienza-Mateo B, Mora-Cuesta VM, Iturbe-Fernández D, Lera-Gómez L, Pérez-Fernández R, Prieto-Peña D, Portilla V, Blanco R, Corrales A, Gualillo O, Cifrián JM, López-Mejías R, González-Gay MA. Endothelial Progenitor Cells: Relevant Players in the Vasculopathy and Lung Fibrosis Associated with the Presence of Interstitial Lung Disease in Systemic Sclerosis Patients. Biomedicines 2021;9:847. [PMID: 34356910 DOI: 10.3390/biomedicines9070847] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 İlgen U, Yayla ME, Düzgün N. Low serum fibroblast growth factor 2 levels not accompanied by increased serum pentraxin 3 levels in patients with systemic sclerosis. Clin Rheumatol 2017;36:367-72. [PMID: 27878407 DOI: 10.1007/s10067-016-3483-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
13 Hashimoto R, Gupte S. Pentose Shunt, Glucose-6-Phosphate Dehydrogenase, NADPH Redox, and Stem Cells in Pulmonary Hypertension. Adv Exp Med Biol 2017;967:47-55. [PMID: 29047080 DOI: 10.1007/978-3-319-63245-2_4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Didier K, Robbins A, Antonicelli F, Pham BN, Giusti D, Servettaz A. [Updates in systemic sclerosis pathogenesis: Toward new therapeutic opportunities]. Rev Med Interne 2019;40:654-63. [PMID: 31301944 DOI: 10.1016/j.revmed.2019.05.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Wu Q, Cao F, Tao J, Li X, Zheng SG, Pan HF. Pentraxin 3: A promising therapeutic target for autoimmune diseases. Autoimmun Rev 2020;19:102584. [PMID: 32534154 DOI: 10.1016/j.autrev.2020.102584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
16 Borghini A, Manetti M, Nacci F, Bellando-Randone S, Guiducci S, Matucci-Cerinic M, Ibba-Manneschi L, Weber E. Systemic Sclerosis Sera Impair Angiogenic Performance of Dermal Microvascular Endothelial Cells: Therapeutic Implications of Cyclophosphamide. PLoS One 2015;10:e0130166. [PMID: 26076019 DOI: 10.1371/journal.pone.0130166] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
17 Huang B, Li J, Zhao J. Screening and identification of potential biomarkers and therapeutic targets for systemic sclerosis-associated interstitial lung disease. Arch Rheumatol 2021;36:548-59. [PMID: 35382367 DOI: 10.46497/ArchRheumatol.2021.8625] [Reference Citation Analysis]
18 Nawata T, Shirai Y, Suzuki M, Kuwana M. Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford) 2021;60:250-5. [PMID: 32699895 DOI: 10.1093/rheumatology/keaa322] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Balbaloglu O, Ozcan SS. Is pentraxin 3 level an effective biomarker in disease activity in patients with rheumatoid arthritis? Arch Med Sci 2020;16:81-6. [PMID: 32051709 DOI: 10.5114/aoms.2017.69726] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
20 Yan YM, Zheng JN, Wu LW, Rao QW, Yang QR, Gao D, Wang Q. Prediction of a Competing Endogenous RNA Co-expression Network by Comprehensive Methods in Systemic Sclerosis-Related Interstitial Lung Disease. Front Genet 2021;12:633059. [PMID: 34290731 DOI: 10.3389/fgene.2021.633059] [Reference Citation Analysis]
21 Odler B, Foris V, Gungl A, Müller V, Hassoun PM, Kwapiszewska G, Olschewski H, Kovacs G. Biomarkers for Pulmonary Vascular Remodeling in Systemic Sclerosis: A Pathophysiological Approach. Front Physiol 2018;9:587. [PMID: 29971007 DOI: 10.3389/fphys.2018.00587] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
22 Sun Z, Wang W, Yu D, Mao Y. Differentially expressed genes between systemic sclerosis and rheumatoid arthritis. Hereditas 2019;156:17. [PMID: 31178673 DOI: 10.1186/s41065-019-0091-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Agilli M, Ekinci S. Assessment of Elevated Pentraxin 3 Levels in Systemic Sclerosis: Comment on the Article by Shirai et al. Arthritis & Rheumatology 2015;67:1408-9. [DOI: 10.1002/art.39033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
24 Lescoat A, Roofeh D, Kuwana M, Lafyatis R, Allanore Y, Khanna D. Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. Clin Rev Allergy Immunol 2021. [PMID: 34468946 DOI: 10.1007/s12016-021-08891-0] [Reference Citation Analysis]
25 Jonasdottir AD, Antovic A, Qureshi AR, Nordin A, Malmström V, Gunnarsson I, Bruchfeld A. Pentraxin-3 - a potential biomarker in ANCA-associated vasculitis. Scand J Rheumatol 2022;:1-9. [PMID: 35383519 DOI: 10.1080/03009742.2022.2045790] [Reference Citation Analysis]
26 Shirai Y, Kawami N, Iwakiri K, Kuwana M. Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis. Journal of Scleroderma and Related Disorders 2022;7:57-61. [DOI: 10.1177/23971983211021747] [Reference Citation Analysis]
27 Mostmans Y, Cutolo M, Giddelo C, Decuman S, Melsens K, Declercq H, Vandecasteele E, De Keyser F, Distler O, Gutermuth J, Smith V. The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review. Autoimmun Rev 2017;16:774-86. [PMID: 28572048 DOI: 10.1016/j.autrev.2017.05.024] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 14.8] [Reference Citation Analysis]
28 Huang X, Zhang L, Duan Y, Wang Y, Wang J. Association of Pentraxin 3 with Autoimmune Diseases: A Systematic Review and Meta-Analysis. Archives of Medical Research 2016;47:223-31. [DOI: 10.1016/j.arcmed.2016.05.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
29 Desbois AC, Cacoub P. Systemic sclerosis: An update in 2016. Autoimmun Rev 2016;15:417-26. [PMID: 26802722 DOI: 10.1016/j.autrev.2016.01.007] [Cited by in Crossref: 104] [Cited by in F6Publishing: 87] [Article Influence: 17.3] [Reference Citation Analysis]
30 Meiners S, Evankovich J, Mallampalli RK. The ubiquitin proteasome system as a potential therapeutic target for systemic sclerosis. Transl Res 2018;198:17-28. [PMID: 29702079 DOI: 10.1016/j.trsl.2018.03.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
31 Atzeni F, Gerardi MC, Barilaro G, Masala IF, Benucci M, Sarzi-puttini P. Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. Expert Review of Clinical Immunology 2018;14:69-82. [DOI: 10.1080/1744666x.2018.1411190] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 5.6] [Reference Citation Analysis]
32 Hughes M, Herrick AL. Digital ulcers in systemic sclerosis. Rheumatology (Oxford) 2017;56:14-25. [PMID: 27094599 DOI: 10.1093/rheumatology/kew047] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 11.5] [Reference Citation Analysis]